INHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia
|
|
- Brice Lindsey
- 5 years ago
- Views:
Transcription
1 The Pancytopenias The Inherited Pancytopenias Pancytopenia refers to a reduction below normal values of all 3 peripheral blood component: leukocytes, platelets, and erythrocytes. Pancytopenia requires microscopic examination of a bone marrow biopsy specimen and a marrow aspirate to assess overall cellularity and morphology. There are 3 general categories of pancytopenia depending on the marrow findings.
2 INHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia Unclassified inherited bone marrow failure syndromes Other genetic syndromes Down syndrome Dubowitz syndrome Seckel syndrome Reticular dysgenesis Schimke immunoosseous dysplasia Familial aplastic anemia (non-fanconi) Cartilage-hair hypoplasia Noonan syndrome
3 Fanconi Anemia Etiology and Epidemiology Fanconi anemia (FA) is primarily inherited in an autosomal recessive manner (one uncommon form is X-linked recessive). It occurs in all racial and ethnic groups. At presentation, patients with FA may have: (1) typical physical anomalies but normal hematologic findings; (2) normal physical features but abnormal hematologic findings; or (3) physical anomalies and abnormal hematologic findings, which constitute the classic phenotype (39% of cases). Approximately 75% of patients are 3-14 yr of age at the time of diagnosis.
4 Pathology Patients have abnormal chromosome fragility, which is seen in metaphase preparations of peripheral blood lymphocytes cultured with phytohemagglutinin and enhanced by adding clastogenic agents such as diepoxybutane (DEB) and mitomycin C. Cell fusion of FA cells with normal cells or with cells from some unrelated patients with FA produces a corrective effect on chromosomal fragility, a process called complementation.
5 Therefore, mutant gene proteins lead to genomic instability, chromosome fragility, and FA. An inability of FA cells to remove oxygen-free radicals, resulting in oxidative damage, is a contributing factor in the pathogenesis.
6 Clinical Manifestations The most common anomaly in FA is hyperpigmentation of the trunk, neck, and intertriginous areas, as well as Cafeau-lait spots and vitiligo, alone or in combination. Half the patients have short stature. Growth failure may be associated with abnormal growth hormone secretion or with hypothyroidism. Absence of radii and thumbs that are hypoplastic, bifid, or absent are common. Anomalies of the feet, congenital hip dislocation, and leg abnormalities are seen.
7 A male patient with FA may have an underdeveloped penis; undescended, atrophic, or absence of the testes; and hypospadias or phimosis. Females can have malformations of the vagina, uterus, and ovary. Many patients have a FA facies, including microcephaly, small eyes, epicanthal folds, and abnormal shape, size, or positioning of the ears.ectopic, pelvic, or horseshoe kidneys are detected by imaging and may show other organs as duplicated, hypoplastic, dysplastic, or absent kidneys. Cardiovascular and gastrointestinal malformations also occur. Approximately 10% of patients with FA are cognitively delayed.
8
9 Laboratory Findings Marrow failure usually ensues in the 1st decade of life. Thrombocytopenia often appears initially, with subsequent onset of granulocytopenia and then macrocytic anemia. Severe aplasia develops in most cases, but its full expression is variable and evolves over a period of months to years. The marrow becomes progressively hypocellular and fatty, like that in severe acquired aplastic anemia.
10 Chromosome fragility is indicated by spontaneously occurring chromatid breaks. For prenatal diagnosis, abnormal chromosome breakage can be tested for in amniotic fluid cells or in tissue from a chorionic villus biopsy.
11 Complications A major feature of the phenotype of FA is the propensity for cancer. The most frequent solid tumors are squamous cell carcinomas of the head, neck, and upper esophagus, followed by carcinomas of the vulva and/or anus, cervix, and lower esophagus. Human papilloma virus is suspected in the pathogenesis. Benign and malignant liver tumors occur (adenomas, hepatomas) and are usually associated with androgen therapy for aplastic anemia. Androgens are also implicated in the etiology of peliosis hepatis (blood-filled hepatic sinusoids).
12 Diagnosis FA should be considered in all children and young adults with unexplained cytopenias. Abnormal hematologic findings and characteristic physical anomalies suggest the diagnosis, which is confirmed with a lymphocyte chromosomal breakage study using DEB.
13 Most patients have stable elevations of serum α- fetoprotein, independent of liver complications or androgen therapy. The laboratory measurement of serum α-fetoprotein can be used as a rapid screening diagnostic test. Specialized laboratories can perform an accurate diagnostic and mutant gene subtyping assay, whereby patient lymphocytes or fibroblasts are studied after exposure to mitomycin C.
14 Treatment A hematologist and a team should supervise patients with FA. If the hematologic findings are stable and there are no transfusion requirements, observation is indicated. Subspecialty consultations for anomalies and disabilities can be arranged during this interval. If growth velocity is below expectations, endocrine evaluation is needed to identify growth hormone deficiency or hypothyroidism. Screening for glucose intolerance and hyperinsulinemia should be performed annually or biannually, depending on the degree of hyperglycemia found on initial testing.
15 Blood counts should be performed every 1-3 mo; bone marrow aspiration and biopsy are indicated annually for leukemia Patients should be assessed for solid tumors at least annually. Beginning at menarche, female patients should be screened annually for gynecologic cancer. Administration of human papilloma virus quadrivalent vaccine to prevent squamous cell carcinoma will likely become a standard intervention.
16 Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic abnormalities. Patients with FA <10 yr old who undergo transplantation using an HLA identical sibling donor have a survival rate >80%. Survival rates are lower for patients undergoing the procedure when >10 yr.
17 Granulocyte colony-stimulating factor (G-CSF) can usually induce an increase in the absolute neutrophil count and occasionally may boost platelet counts and hemoglobin levels.
18 Androgens produce a response in 50% of patients, heralded by reticulocytosis and a rise in hemoglobin within 1-2 mo. White blood cell counts may increase next, followed by platelet counts, but it may take many months to achieve the maximum response.
19 The premise for gene therapy in FA is based on the assumption that corrected hematopoietic cells offer a growth advantage.
20 Prognosis From FA cases reported in the 1990s, the projected median survival was >30 yr of age, an improvement over that in the previous decade. Successes with HSCT have dramatically improved the outlook. Careful surveillance for known complications, especially cancer, and prompt intervention on their detection has also contributed to the improved survival.
21 The Acquired Pancytopenias Etiology and Epidemiology Drugs, chemicals, toxins, infectious agents, radiation, and immune disorders can result in pancytopenia by direct destruction of hematopoietic progenitors, disruption of the marrow microenvironment, or immune-mediated suppression of marrow elements.a careful history of exposure to known risk factors should be obtained for every child presenting with pancytopenia. Even in the absence of the classic associated physical findings, the possibility of a genetic predisposition to bone marrow failure should always be considered. The majority of cases of acquired marrow failure in childhood are idiopathic, in that no causative agent is identified. These are probably immune-mediated through activated T lymphocytes and cytokine destruction of marrow progenitor cells.
22
23 Pathology and Pathogenesis The hallmark of aplastic anemia is peripheral pancytopenia, coupled with hypoplastic or aplastic bone marrow. The severity of the clinical course is related to the degree of myelosuppression. Severe aplastic anemia is defined as a condition in which 2 or more cell components have become seriously compromised (absolute neutrophil count [ANC] <500/mm 3, platelet count <20,000/mm 3, reticulocyte count <1% after correction for hematocrit) in a patient whose bone marrow biopsy material is moderately or severely hypocellular.
24 Approximately 65% of patients who first present with moderate aplastic anemia (ANC 500-1,500/mm 3, platelet count 20, ,000/mm 3, reticulocyte count <1%) eventually progress to meet the criteria for severe disease if they are simply observed. Bone marrow failure may be a consequence of a direct cytotoxic effect on hematopoietic stem cells from a drug or chemical or may result from either cell-mediated or antibody-dependent cytotoxicity.
25 Clinical Manifestations, Laboratory Findings, and Differential Diagnosis Pancytopenia results in increased risks of cardiac failure, infection, bleeding, and fatigue. Acquired pancytopenia is typically characterized by anemia, leukopenia, and thrombocytopenia in the setting of elevated serum cytokine values. Other treatable disorders, such as cancer, collagen vascular disorders, PNH, and infections that may respond to specific therapies (IV immune globulin for parvovirus), should be considered in the differential diagnosis.
26 Careful examination of the peripheral blood smear for RBC, leukocyte, and platelet morphologic features is important. A reticulocyte count should be performed to assess erythropoietic activity. In children, the possibility of congenital pancytopenia must always be considered, and chromosomal breakage analysis should be performed to evaluate for Fanconi anemia.the presence of fetal hemoglobin suggests congenital pancytopenia but is not diagnostic. Bone marrow examination should include both aspiration and a biopsy, and the marrow should be carefully evaluated for morphologic features, cellularity, and cytogenetic findings.
27 Treatment The treatment of children with acquired pancytopenia requires comprehensive supportive care coupled with an attempt to treat the underlying marrow failure. For patients with an HLA-identical sibling marrow donor, allogeneic bone marrow transplantation (BMT) offers a 90% chance of long-term survival. The risks associated with this approach include the immediate complications of transplantation, graft failure, and graft versus host disease. Late adverse effects associated with transplantation may include secondary cancers, cataracts, short stature, hypothyroidism, and gonadal dysfunction. Only 1 in 5 patients has an HLA-matched sibling donor, so matched-related BMT is not an option for the majority of patients.
28 For patients without a sibling donor, the major form of therapy is immunosuppression with antithymocyte globulin (ATG) and cyclosporine, with a response rate of 60-80%.
29 For patients who show no response to immunosuppression or who experience relapse after immunosuppression, matched unrelated donor marrow/stem cell transplant is a treatment option, with a response rate approaching 80% in later studies.
30 Complications The major complications of severe pancytopenia are predominantly related to the risk of life-threatening bleeding from prolonged thrombocytopenia or to infection secondary to protracted neutropenia. Patients with protracted neutropenia due to bone marrow failure are at risk not only for serious bacterial infections but also for invasive mycoses. The general principles of supportive care that have evolved from the use of chemotherapy-related myelosuppression to treat patients with cancer should be fully extended to the care of patients with acquired pancytopenia
31 Prognosis Spontaneous recovery from pancytopenia rarely occurs. If left untreated, severe pancytopenia has an overall mortality rate of approximately 50% within 6 mo of diagnosis and of >75% overall, with infection and hemorrhage being the major causes of morbidity and mortality. The majority of children with acquired severe aplastic anemia show response to allogeneic marrow transplantation or immunosuppression, leaving them with normal or near-normal blood cell counts.
Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationConstitutional Aplastic Anemias. Uma Kundu, M.D. July 17, 2006
Constitutional Aplastic Anemias Uma Kundu, M.D. July 17, 2006 Overview Erythroid lineage only (pure red cell aplasia) Two cell lines (bicytopenia) All hematopoietic cells (aplastic anemia) Aplastic anemias
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationPediatrics. Aplastic Anemia in Children Prognosis and Survival Rate. Definition of Aplastic Anemia. See online here
Pediatrics Aplastic Anemia in Children Prognosis and Survival Rate See online here Aplastic anemia is a rare disease affecting 1 2 people per one million of the population. The hallmark of the disease
More informationCancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Cancer Epidemiology Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Fanconi Anemia Adults, February 2011 Outline Epidemiology FA Literature
More information7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure?
Personalized Medicine: tic Testing and the Implications for Future Therapies Preventiontics Michael Chicka, PhD, Molecular ticist, Preventiontics Founded in 2004 in Marshfield Wisconsin by Dr. Jim Weber
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationAplastic anamia & Sideroblastic anemia
Hematology Lecture 7 كلية التقنيات الصحية والطبية قسم التحليالت المرضية Aplastic anamia & Sideroblastic anemia اإلعداد: ظفر جبار دهاق فؤاد APLASTIC ANEMIA What is Aplastic anemia? Aplastic anemia is a
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationBone marrow failure. By Zahraa Nasooh Al_Saaty
Bone marrow failure By Zahraa Nasooh Al_Saaty Pancytopenia : Pancytopenia describes a reduction in the blood count of all the major cell lines-red cells,white cell and platelets. It has several causes
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationAnemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi
Anemia (3).ms4.25.Oct.15 Hemolytic Anemia Abdallah Abbadi Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k, retics 12%, LDH
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationAPPROACHING TO PANCYTOPENIA
APPROACHING TO PANCYTOPENIA P A T C H A R E E K O M V I L A I S A K, M. D. A S S I S T A N T P R O F E S S O R D I V I S I O N O F P E D I A T R I C H E M A T O L O G Y O N C O L O G Y, D E P A R T M E
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationReducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire -
Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire - Today s Date (MM/DD/YYYY): / / Please note: If you do not want to answer a question, leave it blank. (Note
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationChapter 20: Clinical Management Checklist
Chapter 20: Clinical Management Checklist Introduction Fanconi anemia (FA) is a complex disease that can affect all systems of the body. Patients are at risk for bone marrow failure, leukemia, squamous
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationHematopoietic Cell Transplantation in Bone Marrow Failure Syndromes
Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes The The 44 th th WBMT WBMT SYMPOSIUM 2017 2017 Riyadh, Saudi Saudi Arabia Arabia Mouhab Mouhab Ayas, Ayas, MD MD Department of Pediatric
More informationFanconi Anemia 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Fanconi Anemia 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD FA Camp, August 10, 2012 When You Hear., Think., Or. Horses Zebras Unicorns
More informationLONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS
LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle
More informationEvaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
More informationLeukocytopenias. -lymphocytopenia. -neutropenia. -monocytopenia. BHS seminar 8Nov2014
Leukocytopenias -lymphocytopenia -monocytopenia -neutropenia BHS seminar 8Nov2014 2010 Universitair Ziekenhuis Gent Prof.dr.Lucien Noens, Hematology and Bloodbank, Ghent University hospital Neutrophil
More informationCancer Epidemiology, Manifestations, and Treatment
Cancer Epidemiology, Manifestations, and Treatment Chapter 10 Environmental Risk Factors Tobacco Ø Multipotent carcinogenic mixture Ø Linked to cancers of the lung, lower urinary tract, digestive tract,
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationOneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationChapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia
Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationChapter 2. Diagnostic Evaluation of FA. Definition of Fanconi Anemia. The Importance of Early Diagnosis. Blanche P. Alter, MD, MPH, FAAP
Chapter 2 Diagnostic Evaluation of FA Blanche P. Alter, MD, MPH, FAAP Definition of Fanconi Anemia Fanconi anemia is an autosomal recessive disorder associated with a very high frequency of bone marrow
More information2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationMarrow Failure. Alan D. D Andrea, Niklas Dahl, Eva C. Guinan, and Akiko Shimamura
Marrow Failure Alan D. D Andrea, Niklas Dahl, Eva C. Guinan, and Akiko Shimamura This chapter describes the clinical presentation and molecular basis of two inherited bone marrow failure syndromes, Fanconi
More informationTransplantation Immunology Booklet C
Booklet C Pretest Correct Answers 3. (C) is correct. One of the major barriers to successful hematopoietic stem cell transplantation is the antigens coded for by the major histocompatibility gene complex.
More informationLEARNING ABOUT FANCONI ANEMIA
opyr LEARNING ABOUT FANCONI ANEMIA *Jacqueline Rosenberg *Justin Mark Artwork By: Jacqueline Rosenberg 00 Posters. Ccted. F1000 OVERVIEW Fanconi Anemia (FA) is a rare disease of the blood that leads to
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationConstitutional Hypoplastic Anemia
Kamla-Raj 2002 Int J Hum Genet, 2 (3): 179-184 (2002) Constitutional Hypoplastic Anemia Neelam Varma KEY WORDS Constitutional anemia; congenital; inherited; screening ABSTRACT A large number of patients
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More information7/24/2017. MDS: Understanding Your Diagnosis and Current and Emerging Treatments. Hematopoiesis = Blood Cell Production
: Understanding Your Diagnosis and Current and Emerging Treatments Erica Warlick, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation University of MN Objectives Overview
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationHAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical
More informationWiskott-Aldrich Syndrome
chapter 7 Wiskott-Aldrich Syndrome Wiskott-Aldrich syndrome is a primary immunodeficiency disease involving both T- and B-lymphocytes. In addition, the blood cells that help control bleeding, called platelets
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationShould we still use Camitta s criteria for severe aplastic anemia?
VOLUME 47 ㆍ NUMBER 2 ㆍ June 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Should we still use Camitta s criteria for severe aplastic anemia? Hyun Hwa Yoon, Seok Jae Huh, Ji Hyun Lee, Suee Lee,
More informationGUIDELINES FOR IRRADIATED BLOOD COMPONENTS
GUIDELINES FOR IRRADIATED BLOOD COMPONENTS 1. Policy Statement 2. Definitions 1.1 Blood transfusion services shall have a policy which indicates recipients who are to receive irradiated blood components.
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationA Practical Approach to Leukopenia/Neutropenia in Children. Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014
A Practical Approach to Leukopenia/Neutropenia in Children Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014 Disclosures EPIC trial MAST Therapeutics SUSTAIN trial Selexys Pharmaceuticals
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationBlood Product Modifications: Leukofiltration, Irradiation and Washing
1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationBone Marrow Transplantation for Fanconi Anaemia Using a Fludarabine-based Preparative Regimen with CD34+ Cell Selection
HK J Paediatr (new series) 2006;11:39-44 Bone Marrow Transplantation for Fanconi Anaemia Using a Fludarabine-based Preparative Regimen with CD34+ Cell Selection SY HA, GCF CHAN, AKS CHIANG, ACW LEE, TL
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationBone Marrow Transplantation
Bone Marrow Transplantation Introduction Bone marrow is the spongy tissue inside all of your bones, including your hip and thigh bones. The bone marrow is like a factory that makes different types of blood
More informationLeukemia. There are different types of leukemia and several treatment options for each type.
Leukemia Introduction Leukemia is the name of a group of cancers of the blood cells. Hundreds of thousands of people worldwide are diagnosed with leukemia each year. There are different types of leukemia
More informationHealth Sciences 1111 Module 11 Blood and Lymphatics LAB 11. Watch the video Our Immune System and answer the questions on your worksheet.
Health Sciences 1111 Module 11 Blood and Lymphatics LAB 11 Watch the video Our Immune System and answer the questions on your worksheet. Open Internet Explorer o Go to the Health Sciences Website* and
More informationSHWACHMAN SYNDROME NATURAL HISTORY
SHWACHMAN SYNDROME NATURAL HISTORY Richard M. Pauli, M.D., Ph.D., Midwest Regional Bone Dysplasia Clinics revised 9/2009 INTRODUCTION: The following summary of the medical expectations in Shwachman Syndrome
More informationThe histopathology of bone marrow failure in children
Journal of clinical and experimental hematopathology Vol. 58 No.2, 68-86, 2018 JC lin EH xp ematopathol Review Article The histopathology of bone marrow failure in children Hideto Iwafuchi Bone marrow
More informationHYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist.
HYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist. 1 HYPER IgM SYNDROME Also available : COMMON VARIABLE IMMUNODEFICIENCY
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationPediatric Hematology-Oncology
Pediatric Hematology-Oncology Content Outline In-Training, Initial Certification, and Maintenance of Certification Exams Effective for exams administered beginning April 1, 2019 THE AMERICAN BOARD of PEDIATRICS
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationChapter 13. DiGeorge Syndrome
Chapter 13 DiGeorge Syndrome DiGeorge Syndrome is a primary immunodeficiency disease caused by abnormal migration and development of certain cells and tissues during fetal development. As part of the developmental
More informationGLOSSARY. For use in Shwachman-Diamond Syndrome (SDS)
GLOSSARY For use in Shwachman-Diamond Syndrome (SDS) We wish to thank our Medical Advisors, especially Susan Burroughs, M.D., Peter Durie, M.D. and F. Jean Perrault, M.D. for their assistance in preparation
More informationPediatrics. Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment. Definition. Epidemiology of Pyruvate Kinase Deficiency.
Pediatrics Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment See online here Pyruvate kinase deficiency is an inherited metabolic disorder characterized by a deficiency in the enzyme "pyruvate kinase"
More informationHematopoietic Stem Cell Transplantation for Fanconi Anemia
Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15
More informationChapter 11. Hyper IgM Syndromes
Chapter 11 Hyper IgM Syndromes Patients with Hyper-IgM (HIGM) syndrome are susceptible to recurrent and severe infections and in some types of HIGM syndrome opportunistic infections and an increased risk
More information